Journal of General Internal Medicine

, Volume 23, Issue 11, pp 1809–1814

Screening, Treatment, and Prostate Cancer Mortality in the Seattle Area and Connecticut: Fifteen-year Follow-up

  • Grace Lu-Yao
  • Peter C. Albertsen
  • Janet L. Stanford
  • Therese A. Stukel
  • Elizabeth Walker-Corkery
  • Michael J. Barry
Original Article



Prior to introduction of the prostate-specific antigen (PSA) test, the Seattle–Puget Sound and Connecticut Surveillance, Epidemiology and End Results (SEER) areas had similar prostate cancer mortality rates. Early in the PSA era (1987–1990), men in the Seattle area were screened and treated more intensively for prostate cancer than men in Connecticut.


We previously reported more intensive screening and treatment early in the PSA era did not lower prostate cancer mortality through 11 years and now extend follow-up to 15 years.


Natural experiment comparing two fixed population-based cohorts.


Male Medicare beneficiaries ages 65–79 from the Seattle (N = 94,900) and Connecticut (N = 120,621) SEER areas, followed from 1987–2001.


Rates of prostate cancer screening; treatment with radical prostatectomy, external beam radiotherapy, and androgen deprivation therapy; and prostate cancer-specific mortality.

Main Results

The 15-year cumulative incidences of radical prostatectomy and radiotherapy through 2001 were 2.84% and 6.02%, respectively, for Seattle cohort members, compared to 0.56% and 5.07% for Connecticut cohort members (odds ratio 5.20, 95% confidence interval 3.22 to 8.42 for surgery and odds ratio 1.24, 95% confidence interval 0.98 to 1.58 for radiation). The cumulative incidence of androgen deprivation therapy from 1991–2001 was 4.78% for Seattle compared to 6.13% for Connecticut (odds ratio 0.77, 95% confidence interval 0.67 to 0.87). The adjusted rate ratio of prostate cancer mortality through 2001 was 1.02 (95% C.I. 0.96 to 1.09) in Seattle versus Connecticut.


Among men aged 65 or older, more intensive prostate cancer screening early in the PSA era and more intensive treatment particularly with radical prostatectomy over 15 years of follow-up were not associated with lower prostate cancer-specific mortality.

Key Words

prostate cancer cancer screening men’s health outcomes practice variation 


  1. 1.
    Ries L, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2003. Bethesda, MD: National Cancer Institute; ; 2006.Google Scholar
  2. 2.
    Hankey B, Feuer E, Clegg L, et al. Cancer surveillance series: Interpreting trends in prostate cancer - Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017–24.PubMedCrossRefGoogle Scholar
  3. 3.
    Feuer E, Merrill R, Hankey B. Cancer surveillance series: Interpreting trends in prostate cancer - Part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999;91:1025–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981–90.PubMedGoogle Scholar
  5. 5.
    Shaw P, Etzioni R, Zeliadt S, et al. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol. 2004;160:1059–69.PubMedCrossRefGoogle Scholar
  6. 6.
    Potosky A, Feuer E, Levin D. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiologic Reviews. 2001;23:181–6.PubMedGoogle Scholar
  7. 7.
    Albertsen P. The prostate cancer conundrum. J Natl Cancer Inst. 2003;95:930–1.PubMedCrossRefGoogle Scholar
  8. 8.
    Damber J. Decreasing mortality rates for prostate cancer: possible role of hormonal therapy. BJU International. 2004;93:695–701.PubMedCrossRefGoogle Scholar
  9. 9.
    Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 2002;325:740–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Smith R, Cokkinides V, Eyre H. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006;56:11–25.PubMedCrossRefGoogle Scholar
  11. 11.
    Oleynick JU, Albertsen PC, Barry MJ, Walker-Corkery ES, Yao SL, Lu-Yao GL. Utility of the SEER-Medicare data to identify medical androgen deprivation therapy. J Clin Onc. 2006;24:6113.Google Scholar
  12. 12.
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Medical Care. 2002;40:IV–3–18.Google Scholar
  13. 13.
    McCullagh P, Nelder J. Generalized Linear Models. London: Chapman and Hall; 1989.Google Scholar
  14. 14.
    Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society, Series B, Methodological. 1972;34:187–220.Google Scholar
  15. 15.
    D’Agostino R, Lee M, Belanger A. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Statistics in Medicine. 1990;9:1501–15.PubMedCrossRefGoogle Scholar
  16. 16.
    Concato J, Wells CK, Horwitz RI, et al. The Effectiveness of screening for prostate cancer: A nested case-control study. Arch Intern Med. 2006;166:38–43.PubMedCrossRefGoogle Scholar
  17. 17.
    Oberaigner W, Horninger W, Klocker H, Schonitzer D, Stuhlinger W, Bartsch G. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol. 2006;164:376–84.PubMedCrossRefGoogle Scholar
  18. 18.
    Wong Y, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296:2683–93.PubMedCrossRefGoogle Scholar
  19. 19.
    Lu-Yao G, Greenberg ER. Changes in prostate cancer incidence and treatment in the USA. Lancet. 1994;343:251–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Newschaffer CJ, Otani K, McDonald MK, Penberthy LT. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst. 2000;92:613–.PubMedCrossRefGoogle Scholar
  21. 21.
    Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977–84.PubMedCrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2008

Authors and Affiliations

  • Grace Lu-Yao
    • 1
  • Peter C. Albertsen
    • 2
  • Janet L. Stanford
    • 3
  • Therese A. Stukel
    • 4
  • Elizabeth Walker-Corkery
    • 5
  • Michael J. Barry
    • 5
  1. 1.The Cancer Institute of New JerseyRobert Wood Johnson Medical SchoolNew BrunswickUSA
  2. 2.Division of UrologyThe University of Connecticut Health CenterFarmingtonUSA
  3. 3.Division of Public Health Sciences, Programs in Epidemiology and Prostate CancerFred Hutchinson Cancer Research CenterSeattleUSA
  4. 4.Institute for Clinical Evaluative SciencesTorontoCanada
  5. 5.Medical Practices Evaluation CenterMassachusetts General HospitalBostonUSA

Personalised recommendations